Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05908825 · ClinicalTrials.gov registry record · NA

Placebo-Controlled Study Assessing the Use of a Novel Exfoliative Serum With A Chemical Peel to Improve Photodamage in Adults

A NA study, sponsored by Austin Institute for Clinical Research.

Completed
Registry status
NA
Development phase
34
Enrollment target

NCT05908825: Completed NA study, sponsored by Austin Institute for Clinical Research.

NCT05908825 is a NA study that has completed, run by Austin Institute for Clinical Research. The registered enrollment target is 34 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05908825, a NA study, has completed, sponsored by Austin Institute for Clinical Research.

COMPLETED
Registry status
NA
Development phase
34 participants
Enrollment target

Study Summary

This is a split-face, double-blind, placebo-controlled study assessing the use of a novel exfoliative serum with a chemical peel to improve photodamage in healthy female subjects between the ages of 30 and 65 years, inclusive, with Fitzpatrick skin types I-VI.

Primary Outcome

Product tolerability will be measured using the clinical grading of tolerance by evaluating the subjects reported local facial cutaneous tolerability including burning, stinging, and itching. Each scale will be measured with the following parameters, 0 = none (best possible outcome), 1 = mild, 2 = moderate, and 3 = severe (worst possible outcome). A decrease in scores or lack of significant increase indicates tolerability of the study treatment. The null hypothesis is that the mean change from b

Interventions

  • DRUG Vitamin C with AHA Exfoliative Serum
  • DRUG Placebo serum

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2023-06-22
Est. Completion 2024-01-26
Phase NA

What the finished NCT05908825 record still lists

NCT05908825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which Vitamin C with AHA Exfoliative Serum is the first listed.

NCT05908825 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05908825 about?

NCT05908825 is a clinical study titled "Placebo-Controlled Study Assessing the Use of a Novel Exfoliative Serum With A Chemical Peel to Improve Photodamage in Adults". This is a split-face, double-blind, placebo-controlled study assessing the use of a novel exfoliative serum with a chemical peel to improve photodamage in healthy female subjects between the ages of 30 and 65 years, inclusive, with Fitzpatrick skin types I-VI.

What is the current status of trial NCT05908825?

This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2023-06-22. Estimated completion is 2024-01-26.

What interventions are being tested in trial NCT05908825?

The interventions under investigation include: Vitamin C with AHA Exfoliative Serum (DRUG), Placebo serum (DRUG).

Who is sponsoring clinical trial NCT05908825?

This trial is sponsored by Austin Institute for Clinical Research, which has 6 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05908825's enrollment target sits among peer trials

34 1570th of 2000 higher than 427 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05908825, the US trial registry maintained by the National Library of Medicine. NCT05908825 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.